As filed with the Securities and Exchange Commission on May 9, 2019

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM S-8

**REGISTRATION STATEMENT** 

UNDER

THE SECURITIES ACT OF 1933

### **Corvus Pharmaceuticals, Inc.**

(Exact name of Registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

**46-4670809** (I.R.S. Employer Identification Number)

863 Mitten Road, Suite 102

Burlingame, CA 94010 (650) 900-4520

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**2016 Equity Incentive Award Plan** (Full Title of the Plan)

Richard A. Miller, M.D. President and Chief Executive Officer Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame, CA 94010 (650) 900-4520

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Alan C. Mendelson, Esq. Latham & Watkins LLP 140 Scott Drive Menlo Park, CA 94025 Telephone: (650) 328-4600 Facsimile: (650) 463-2600

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	0	Accelerated filer	х
Non-accelerated filer	0	Smaller reporting company	х
		Emerging growth company	х

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. x

#### CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Amount to be Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Share <sup>(2)</sup>	1	Proposed Maximum Aggregate Offering Price Per Share	Amount of Registration Fee
Common Stock, \$0.0001 par value per share	1,170,000(3) \$	4.03	\$	4,715,100	\$ 571.47

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2016 Equity Incentive Award Plan (the "2016 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock.

(2) This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant's common stock as reported on The Nasdaq Global Select Market on May 8, 2019, which is \$4.03.

(3) Represents the additional shares of common stock available for future issuance under the 2016 Plan resulting from an annual increase as of January 1, 2019.

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.

#### EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,170,000 shares of the Registrant's common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590 and 333-223622) are effective, as a result of the operation of an automatic annual increase provision therein.

## INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016, March 10, 2017 and March 13, 2018 (File Nos. 333-210456, 333-216590 and 333-223622) are incorporated by reference herein.

#### Exhibit Index

Exhibit		Incorporated by Reference		Filed	
Number	Exhibit Description	Form	Date	Number	Herewith
4.1	Amended and Restated Certificate of Incorporation.	8-K	3/29/2016	3.1	
4.2	<u>Amended and Restated Bylaws.</u>	8-K	3/29/2016	3.2	
4.3	Form of Common Stock Certificate.	S-1	1/4/2016	4.2	
4.4	Amended and Restated Investors' Rights Agreement, dated September 16, 2015,	S-1/A	2/8/2016	4.3	
	by and among Corvus Pharmaceuticals, Inc. and the investors listed therein.				
5.1	Opinion of Latham & Watkins LLP.				Х
23.1	Consent of independent registered public accounting firm.				Х
23.2	Consent of Latham & Watkins LLP (included in Exhibit 5.1).				Х
24.1	Power of Attorney. Reference is made to the signature page to the Registration				Х
	Statement.				
99.2(a)#	2016 Equity Incentive Award Plan.	S-8	3/29/2016	99.2(a)	
99.2(b)#	Form of Stock Option Grant Notice and Stock Option Agreement under the 2016	S-1	1/4/2016	10.5(b)	
	Equity Incentive Award Plan.				
99.2(c)#	Form of Restricted Stock Award Agreement and Restricted Stock Unit Award	S-1	1/4/2016	10.5(c)	
	Agreement under the 2016 Equity Incentive Award Plan.				
99.2(d)#	Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit	S-1	1/4/2016	10.5(d)	
	Award Grant Notice under the 2016 Equity Incentive Award Plan.				

#Indicates management contract or compensatory plan.

3

#### SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Burlingame, California, on this 9th day of May, 2019.

#### **Corvus Pharmaceuticals, Inc.**

By:

/s/ Richard A. Miller Richard A. Miller, M.D. President and Chief Executive Officer

#### POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

Signature	Title	Date
/s/ Richard A. Miller Richard A. Miller M.D.	President, Chief Executive Officer and Director (Principal Executive Officer)	May 9, 2019
/s/ Leiv Lea Leiv Lea	Chief Financial Officer (Principal Financial and Accounting Officer)	May 9, 2019
/s/ Ian T. Clark Ian T. Clark	Director	May 9, 2019
/s/ Elisha P. (Terry) Gould Elisha P. (Terry) Gould	Director	May 9, 2019
/s/ Linda S. Grais, M.D. Linda S. Grais, M.D.	Director	May 9, 2019
/s/ Steve E. Krognes Steve E. Krognes	Director	May 9, 2019
/s/ Scott W. Morrison Scott W. Morrison	Director	May 9, 2019
/s/ Peter Thompson, M.D. Peter Thompson, M.D.	Director	May 9, 2019
-	4	

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com

#### FIRM / AFFILIATE OFFICES

Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan

Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Singapore Tokyo Washington, D.C.

# 

May 9, 2019

Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame, CA 94010

Re: Registration Statement on Form S-8; 1,170,000 shares of Common Stock of Corvus Pharmaceuticals, Inc., par value \$0.0001 per share

Ladies and Gentlemen:

We have acted as special counsel to Corvus Pharmaceuticals, Inc., a Delaware corporation (the "*Company*"), in connection with the registration by the Company of an aggregate of 1,170,000 shares of common stock of the Company, par value \$0.0001 per share (the "*Common Stock*") (the "*Shares*") issuable under the 2016 Equity Incentive Award Plan (the "*Plan*").

The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the "*Act*"), filed with the Securities and Exchange Commission (the "*Commission*") on May 2, 2019 (the "*Registration Statement*"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the "*DGCL*"), and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Plan, assuming in each case that the individual issuances, grants or awards under the Plan are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Latham & Watkins LLP



#### CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Corvus Pharmaceuticals, Inc. of our report dated March 7, 2019 relating to the financial statements, which appears in Corvus Pharmaceuticals, Inc.'s <u>Annual Report on Form 10-K for the year ended December 31, 2018.</u>

/s/ PricewaterhouseCoopers LLP San Jose, California May 9, 2019